Modality
Degrader
MOA
TYK2i
Target
DLL3
Pathway
Apoptosis
LN
Development Pipeline
Preclinical
~Apr 2016
→ ~Jul 2017
Phase 1
~Oct 2017
→ ~Jan 2019
Phase 2
~Apr 2019
→ ~Jul 2020
Phase 3
~Oct 2020
→ ~Jan 2022
NDA/BLA
Apr 2022
→ Feb 2025
NDA/BLACurrent
NCT06862621
2,210 pts·LN
2022-04→2025-02·Recruiting
2,210 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-02-201.1y agoPh3 Readout· LN
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2025-02-20 · 1.1y ago
LN
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06862621 | NDA/BLA | LN | Recruiting | 2210 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 |